About OSE Immunotherapeutics
OSE Immunotherapeutics is a company based in Nantes (France) founded in 1986.. The company has 64 employees as of December 31, 2024. OSE Immunotherapeutics offers products and services including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument. OSE Immunotherapeutics operates in a competitive market with competitors including Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech, among others.
- Headquarter Nantes, France
- Employees 64 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ose Immunotherapeutics Sa
-
Annual Revenue
$72.6 M (USD)3037.72as on Dec 31, 2024
-
Net Profit
$38.91 M (USD)0as on Dec 31, 2024
-
EBITDA
$29.46 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$9.12 M (USD), Grant
Apr 10, 2024
- Investors
-
Employee Count
64
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OSE Immunotherapeutics
OSE Immunotherapeutics is a publicly listed company on the EURONEXT with ticker symbol OSE in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OSE Immunotherapeutics
OSE Immunotherapeutics offers a comprehensive portfolio of products and services, including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Immunotherapy for activating T cells in cancer treatment.
Targets tumor microenvironment for oncology applications.
Regulates immune responses in inflammation disorders.
Modulates T cell activity for therapeutic use.
Funding Insights of OSE Immunotherapeutics
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $9.1M
-
First Round
First Round
(20 Jun 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Grant - OSE Immunotherapeutics | Valuation |
investors |
|
| Jun, 2023 | Amount | Grant - OSE Immunotherapeutics | Valuation |
investors |
|
| Jun, 2017 | Amount | Post-IPO - OSE Immunotherapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OSE Immunotherapeutics
OSE Immunotherapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bpifrance. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OSE Immunotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OSE Immunotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ose Immunotherapeutics Comparisons
Competitors of OSE Immunotherapeutics
OSE Immunotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Medical solutions for transplant patients are developed and provided.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ose Immunotherapeutics
Frequently Asked Questions about OSE Immunotherapeutics
When was OSE Immunotherapeutics founded?
OSE Immunotherapeutics was founded in 1986 and raised its 1st funding round 31 years after it was founded.
Where is OSE Immunotherapeutics located?
OSE Immunotherapeutics is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
How many employees does OSE Immunotherapeutics have?
As of Dec 31, 2024, the latest employee count at OSE Immunotherapeutics is 64.
What is the annual revenue of OSE Immunotherapeutics?
Annual revenue of OSE Immunotherapeutics is $72.6M as on Dec 31, 2024.
What does OSE Immunotherapeutics do?
Founded in 1986 in Nantes, France, the company operates in the biotechnology sector, focusing on immunotherapies for immuno-oncology and autoimmune conditions. Key developments include the Tedopi vaccine targeting lung, ovarian, and pancreatic cancers, alongside the CoVepiT vaccine for COVID-19, OSE-172 and CLEC-1 for various cancers, a bispecific fusion protein platform, OSE-127 for ulcerative colitis and Sjogrens syndrome, FR104 for autoimmune diseases and transplantation, and OSE-230 for inflammation.
Who are the top competitors of OSE Immunotherapeutics?
OSE Immunotherapeutics's top competitors include CareDx, ADMA Biologics and BioNTech.
What products or services does OSE Immunotherapeutics offer?
OSE Immunotherapeutics offers Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument.
Is OSE Immunotherapeutics publicly traded?
Yes, OSE Immunotherapeutics is publicly traded on EURONEXT under the ticker symbol OSE.
Who are OSE Immunotherapeutics's investors?
OSE Immunotherapeutics has 1 investor. Key investors include Bpifrance.
What is OSE Immunotherapeutics's ticker symbol?
The ticker symbol of OSE Immunotherapeutics is OSE on EURONEXT.